PE20000701A1 - Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana - Google Patents
Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humanaInfo
- Publication number
- PE20000701A1 PE20000701A1 PE1999000538A PE00053899A PE20000701A1 PE 20000701 A1 PE20000701 A1 PE 20000701A1 PE 1999000538 A PE1999000538 A PE 1999000538A PE 00053899 A PE00053899 A PE 00053899A PE 20000701 A1 PE20000701 A1 PE 20000701A1
- Authority
- PE
- Peru
- Prior art keywords
- apomorphine
- fentholamine
- treatment
- dysfunction
- combination
- Prior art date
Links
- 229960004046 apomorphine Drugs 0.000 title abstract 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title 1
- 230000036299 sexual function Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 abstract 1
- -1 4-METHYLPHENYL Chemical class 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 229950002475 mesilate Drugs 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)FENTOLAMINA (3-[[[4,5-DIHIDRO-1H-IMIDAZOL-2-IL)METIL](4-METILFENIL)AMINO]FENOL) Y LA SAL (CLORHIDRATO O MESILATO DE FENTOLAMINA), SOLVATO, HIDRATO, FORMA CRISTALINA, BASE; b)APOMORFINA, SAL (CLORHIDRATO DE APOMORFINA), SOLVATO, HIDRATO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL, DISFUNCION ERECTIL MASCULINA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/100,562 US6011043A (en) | 1998-06-19 | 1998-06-19 | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000701A1 true PE20000701A1 (es) | 2000-08-16 |
Family
ID=22280390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000538A PE20000701A1 (es) | 1998-06-19 | 1999-06-17 | Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6011043A (es) |
| EP (1) | EP1087767A2 (es) |
| AR (1) | AR019327A1 (es) |
| AU (1) | AU4676099A (es) |
| CA (1) | CA2334924A1 (es) |
| CO (1) | CO5050343A1 (es) |
| PE (1) | PE20000701A1 (es) |
| WO (1) | WO1999065475A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
| AU4203600A (en) * | 1999-04-06 | 2000-10-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| CA2479372A1 (en) * | 2002-03-19 | 2003-10-02 | Michael Holick | Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| DK2561860T3 (en) * | 2002-05-31 | 2018-04-30 | Titan Pharmaceuticals Inc | Implantable polymer device for prolonged release of buprenorphine |
| GB0221711D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods |
| KR101152183B1 (ko) * | 2003-03-31 | 2012-06-15 | 타이탄 파머슈티컬즈 인코퍼레이티드 | 도파민 아고니스트의 지속 방출을 위한 이식가능한 폴리머디바이스 |
| CA2601773A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
| US5236904A (en) * | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
| BR9203277A (pt) * | 1992-08-21 | 1994-03-01 | Cesar Roberto Dias Nahoum | Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| ES2270517T3 (es) * | 1997-05-19 | 2007-04-01 | Zonagen, Inc. | Terapia de combinacion para modular la respuesta sexual humana. |
-
1998
- 1998-06-19 US US09/100,562 patent/US6011043A/en not_active Expired - Fee Related
-
1999
- 1999-06-17 EP EP99930164A patent/EP1087767A2/en not_active Withdrawn
- 1999-06-17 CO CO99037999A patent/CO5050343A1/es unknown
- 1999-06-17 AU AU46760/99A patent/AU4676099A/en not_active Abandoned
- 1999-06-17 AR ARP990102919A patent/AR019327A1/es unknown
- 1999-06-17 CA CA002334924A patent/CA2334924A1/en not_active Abandoned
- 1999-06-17 PE PE1999000538A patent/PE20000701A1/es not_active Application Discontinuation
- 1999-06-17 WO PCT/US1999/012805 patent/WO1999065475A2/en not_active Ceased
- 1999-10-08 US US09/415,082 patent/US6136818A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1087767A2 (en) | 2001-04-04 |
| US6136818A (en) | 2000-10-24 |
| US6011043A (en) | 2000-01-04 |
| CO5050343A1 (es) | 2001-06-27 |
| AR019327A1 (es) | 2002-02-13 |
| WO1999065475A3 (en) | 2000-04-06 |
| WO1999065475A2 (en) | 1999-12-23 |
| AU4676099A (en) | 2000-01-05 |
| CA2334924A1 (en) | 1999-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2002000195A (es) | Compuestos farmaceuticamente activos ref. pcs10342 afae/bb | |
| BR0316305A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit | |
| NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| LU90856I2 (fr) | Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables | |
| LU91650I2 (fr) | Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| PA8484301A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
| PE20000701A1 (es) | Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana | |
| MXPA05013733A (es) | 2-aminobenzotiazoles como agonistas inversos del receptor de cb1. | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| ZA200104146B (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males. | |
| IL146003A0 (en) | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | |
| EA200200207A1 (ru) | Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы | |
| PE20020210A1 (es) | Indoloquinazolinonas como inhibidores de poli(adp-ribosa)polimerasa (parp) | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| CR7936A (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus sitemico eritematoso | |
| AP2005003325A0 (en) | Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction | |
| EA200100089A1 (ru) | Предотвращение рецидива мигрени | |
| PE20050665A1 (es) | ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL | |
| BR0110450A (pt) | Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual | |
| AR033965A1 (es) | Uso de un antagonista de tnfalfa, para tratar o inhibir la lesion celular o la muerte de las celulas | |
| AU6321899A (en) | The use of dopaminergic agents in the management of sexual dysfunction | |
| AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |